AS2717638
目录号 : GC31904
An LPA5 antagonist
Cas No.:2148339-28-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
AS-2717638 is a lysophosphatidic acid receptor 5 (LPA5) antagonist (IC50 = 0.038 ?M).1 It is selective for LPA5 over LPA1, LPA2, and LPA3 (IC50s = >10 ?M for all) but also binds to adenosine A1 and μ-opioid receptors at 10 ?M. It induces analgesia in a rat model of allodynia induced by LPA or geranylgeranyl pyrophosphate when administered at doses of 3, 10, and 30 mg/kg. AS-2717638 (10 and 30 mg/kg) inhibits allodynia induced by prostaglandin E2 , PGF2α, or AMPA in rats. It increases the paw withdrawal threshold and latency in the von Frey hair and plantar tests, respectively, in rats when administered at a dose of 10 mg/kg.
1.Murai, N., Hiyama, H., Kiso, T., et al.Analgesic effects of novel lysophosphatidic acid receptor 5 antagonist AS2717638 in rodentsNeuropharmacology12697-107(2017)
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2347 mL | 11.1737 mL | 22.3474 mL |
| 5 mM | 0.4469 mL | 2.2347 mL | 4.4695 mL |
| 10 mM | 0.2235 mL | 1.1174 mL | 2.2347 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。